Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate
CAS 19542-74-6
Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate (CAS 19542-74-6) is a pharmaceutical compound with 0 bioactivity targets and 5 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate is linked to DTXSID10941314 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate used for in pharmaceutical contexts?
Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate (CAS 19542-74-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate?
Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate has 5 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Blindness, Cholecystitis, Urosepsis, Visual acuity reduced. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Acetyl Cysteinate with EU status "permitted".
What clinical phase is Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate in?
No phase 1-4 clinical development badge is rendered for Sodium N-(1-carboxy-2-sulfanylethyl)ethanimidate because the matched compound identifier rows do not contain a max-phase value.